Evidence map›Paper›PMID 21311223›Full record

ArticleCell cycle (Georgetown, Tex.)2011

Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression.

Marina Kolesnichenko, Peter K Vogt

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marina KolesnichenkoDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA. marinak@scripps.edu
Peter K Vogt
La Jolla Alcohol Research · US

Funding

Small Molecules and Targeted Gene Delivery in Tumor AngiogenesisP01CA078045 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI VOGT, PETER K · 1998 to 2008
$10.2M
P3K, RETROVIRAL ONCOGENE AND HOMOLOG OF PI 3-KINASER01CA078230 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI VOGT, PETER K · 1998 to 2013
$5.6M
NCI NIH HHS P01 CA078045NCI NIH HHS R01 CA078230
6 · The paper itself

Abstract

PLZF can function as a transcriptional activator or as a transcriptional repressor. Recent studies have identified two direct transcriptional targets of PLZF, REDD1 and smooth muscle α-actin. REDD1 is activated by PLZF. It mediates the PLZF-dependent downregulation of TORC1 and is responsible for the maintenance of pluripotency in cultures of spermatogonial progenitor cells. This activity may extend to other stem-like cell types. The effect of REDD1 on TORC1 also raises the possibility that REDD1 controls cell growth, tumorigenicity and senescence. The regulatory loop extending from PLZF via REDD1 to TORC1 identifies REDD1 as a critical determinant of TOR activity. The transcription of smooth muscle α-actin is repressed by PLZF. In fibroblasts, this downregulation is accompanied by a change of cell shape and a dramatic reorganization of the cytoskeleton. It is also correlated with the acquisition of cellular resistance to oncogenic transformation. The resistance is selective, it works against some oncoproteins but not against others. The molecular mechanisms underlying the changes in the cytoskeleton and in the susceptibility to oncogenic transformation are unknown. However these changes are dependent on the activity of RAS and thus probably involve the RAC/RHO family of proteins.

Indexed as

Cellular SenescenceActinsAnimalsCytoskeletonFibroblastsHumansKruppel-Like Transcription FactorsMaleMiceMuscle, SmoothPromyelocytic Leukemia Zinc Finger ProteinSignal TransductionSpermatogoniaStem CellsTranscription FactorsTumor Suppressor ProteinsActinsCRTC1 protein, humanDDIT4 protein, humanKruppel-Like Transcription FactorsPromyelocytic Leukemia Zinc Finger ProteinTranscription FactorsTumor Suppressor ProteinsZBTB16 protein, human

Identifiers

PMID21311223
PMCPMC3100790
OpenAlexW2045052990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.